natgillin/translations-raw huggingface dataset:
Resistance to fluoroquinolones, including delafloxacin, can occur due to mutations in defined regions of the target bacterial enzymes topoisomerase IV and DNA gyrase referred to as Quinolone-Resistance Determining Regions (QRDRs), or through other resistance mechanisms such as efflux mechanisms. 
Odpornost na fluorokinolone, vključno z delafloksacinom, se lahko pojavi zaradi mutacij v določenih regijah tarčnih bakterijskih encimov topoizomeraze IV in DNA-giraze, t.i. regije kinolonskih odpornostnih determinant (QRDRs - Quinolone-Resistance Determining Regions), ali prek drugih mehanizmov odpornosti kot so mehanizmi izlivnih črpalk.
Peak plasma delafloxacin concentrations are achieved at the end of the 1 hour intravenous infusion. 
Najvišje plazemske koncentracije delafloksacina so doseţ ene ob koncu 1-urne intravenske infuzije.
Sinus tachycardia Palpitations Bradycardia 
Sinusna tahikardija Palpitacije Bradikardija
In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department. 
Ob nenadni bolečini v trebuhu, hrbtu ali prsnem košu se bolnikom priporoča, da se nemudoma posvetujejo z zdravnikom na urgentnem oddelku.
Delafloxacin should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice. 
Zdravljenje z delafloksacinom je treba prenehati takoj ob prvih znakih ali simptomih kakršnih koli resnih neţ elenih učinkov, bolniku pa je treba svetovati, naj se posvetuje z zdravnikom, ki mu je zdravilo predpisal.
If superinfection occurs during therapy, appropriate measures should be taken. 
Če pride med zdravljenjem do superinfekcije, je potrebno ustrezno ukrepati.
Patients under treatment with delafloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition (see section 4.8). 
Bolnike, ki se zdravijo z delafloksacinom, je treba opozoriti, da pred nadaljevanjem zdravljenja obvestijo svojega zdravnika, če se pojavijo simptomi nevropatije, kot so bolečina, pekoč občutek, mravljinčenje, odrevenelost ali šibkost, da se prepreči razvoj potencialno nepovratnega stanja (glejte poglavje 4.8).
Quofenix will be given to you by a nurse or doctor via an infusion (drip) into a vein. 
Zdravilo Quofenix vam bo dal zdravnik ali medicinska sestra v obliki infuzije (kapanja) v ţ ilo.
The fAUC24/MIC ratio, as for other quinolone antibiotics, resulted in the pharmacokinetic/ pharmacodynamic parameter most closely associated with the efficacy of delafloxacin. 
Razmerje fAUC24/MIK je, tako kot pri drugih kinolonskih antibiotikih, privedlo do farmakokinetičnega/farmakodinamičnega parametra, ki je najbolj povezan z učinkovitostjo delafloksacina.
Therefore, no dosage adjustment is necessary. 
Zato prilagajanje odmerkov ni potrebno.
The tablets are swallowed whole with a sufficient amount of water, and can be taken with or without food. 
Tablete je potrebno pogoltniti cele z dovolj veliko količino tekočine, lahko se jih vzame s hrano ali brez hrane.
Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted. 
Obvestite svojega zdravnika, če imate teţ ave z ledvicami, ker je v teh primerih potrebno odmerke prilagoditi.
There are no data concerning an interaction of intravenous delafloxacin with multivitamins, other supplements or didanosine. 
Podatkov o medsebojnem delovanju intravensko uporabljenega delafloksacina z multivitamini, drugimi dodatki ali didanozinom ni.
It is unknown whether delafloxacin/metabolites are excreted in human milk. 
Ni znano ali se delafloksacin/presnovki izločajo v materino mleko.
• You or a member of your family is known to have a deficiency in glucose-6-phosphate dehydrogenase. 
• sami ali katerikoli član vaše druţine trpi za pomanjkanjem glukoza-6-fosfat-dehidrogenaze.
As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported (see section 4.8), usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g., glibenclamide) or with insulin. 
Tako kot pri vseh kinolonih so poročali o motnjah vrednosti glukoze v krvi, vključno s hipoglikemijo in hiperglikemijo (glejte poglavje 4.8), običajno pri sladkornih bolnikih, ki so se sočasno zdravili s peroralnimi antidiabetiki (npr. glibenklamid) ali z insulinom.
By blocking these enzymes, Quofenix kills bacteria that cause the infection. 
Z blokiranjem teh encimov, zdravilo Quofenix ubije bakterije, ki povzročajo okuţ bo.
Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur as early as within 48 hours of starting treatment with quinolones and fluoroquinolones and have been reported to occur even up to several months after discontinuation of treatment. 
Tendinitis in ruptura tetive (zlasti, a ne izključno, Ahilove tetive), včasih obojestransko, se lahko pojavita ţ e v 48 urah po začetku zdravljenja s kinoloni in fluorokinoloni, o njiju pa so poročali tudi še več mesecev po prenehanju zdravljenja.
The steady state volume of distribution of delafloxacin is about 40 L which approximates total body water. 
V stanju dinamičnega ravnovesja je volumen porazdelitve delafloksacina je pribliţ no 40 l, kar pribliţ no ustreza celotni količini vode v telesu.
Paediatric population Quofenix is contraindicated in children and adolescents (see section 4.3). 
Pediatrična populacija Zdravilo Quofenix je kontraindicirano pri otrocih in mladostnikih (glejte poglavje 4.3).
Some adverse drug reactions (e.g. dizziness, headache, visual disorders) may impair the patient's ability to concentrate and react, and therefore may constitute a risk in situations where the patient operates an automobile or machinery or engages in other activities requiring mental alertness and coordination. 
Nekateri neţ eleni učinki (npr. omotica, glavobol, motnje vida) lahko poslabšajo bolnikovo koncentracijo in sposobnost reagiranja, zato lahko predstavljajo tveganje v okoliščinah, ko bolnik upravlja z avtomobilom ali stroji ali se ukvarja z drugimi dejavnostmi, ki zahtevajo mentalno pozornost in usklajenost gibov.
• Increase in the amount of enzymes produced by your liver called transaminases -shown in blood tests 
• povečanje vrednosti encimov, ki nastajajo v jetrih, imenovanih transaminaze, kar kaţejo krvne preiskave
At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with delafloxacin should be discontinued and alternative treatment should be considered. 
Ob prvem znaku tendinitisa (npr. boleča oteklina, vnetje) je treba zdravljenje z delafloksacinom prenehati in razmisliti o drugačnem zdravljenju.
• Cold sweat 
• hladen znoj
Millmount Healthcare Block-7, City North Business Campus, Stamullen, Co. Meath Ireland or 
Millmount Healthcare Block-7, City North Business Campus, Stamullen, Co. Meath Irska ali
MillMount Healthcare Block-7, City North Business Campus, Stamullen, Co. Meath Ireland or 
MillMount Healthcare Block-7, City North Business Campus, Stamullen, Co. Meath Irska ali
Organism 
Organizem
A tendon is the cord that joins your muscle to your skeleton. 
Tetiva (kita) je »vrvica«, ki pritrjuje mišice na vaše okostje.
Clinically significant gender-related differences in delafloxacin pharmacokinetics have not been observed in healthy subjects or in patients with ABSSSI. 
Klinično pomembnih razlik, povezanih s spolom, pri farmakokinetiki delafloksacina niso zaznali niti pri zdravih osebah niti pri bolnikih z ABSSSI.
• Seasonal allergy 
• sezonske alergije
Each tablet contains 39 mg of sodium. 
Ena tableta vsebuje 39 mg natrija.
Hypersensitivity (see section 4.4) Seasonal allergy 
Preobčutljivost (glejte poglavje 4.4) Sezonska alergija
Gram-negative micro-organisms: 
Gramnegativni mikroorganizmi:
What Quofenix is and what it is used for 
Kaj je zdravilo Quofenix in za kaj ga uporabljamo
Therefore, delafloxacin should be taken at least 2 hours before or 6 hours after these agents. 
Delafloksacin je zato potrebno vzeti najmanj 2 uri pred oziroma 6 ur po zauţ itju zgoraj omenjenih učinkovin.
There are no available data concerning specific effects of other medicinal products on delafloxacin. 
Ni razpoloţ ljivih podatkov o posebnih učinkih drugih zdravil na delafloksacin.
This medicinal product does not require any special storage conditions if kept unopened in the original container. 
Za shranjevanje zdravila ni posebnih navodil, če ga shranjujete zaprtega v originalni ovojnini.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neţ elenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
Cross-resistance between delafloxacin and other fluoroquinolones may be observed, although some isolates resistant to other fluoroquinolone may retain susceptibility to delafloxacin. 
Opaţ ena je lahko navzkriţ na odpornost med delafloksacinom in drugimi fluorokinoloni, čeprav lahko nekateri izolati, odporni na druge fluorokinolone, ohranijo občutljivost na delafloksacin.
• Irregular or rapid heart beats, feeling your heart beat (palpitation), decrease of heart beat 
• nepravilno ali hitro utripanje srca, občutek bitja srca (palpitacije), počasno bitje srca
Serious side effects 
Resni neţeleni učinki
- Drop in blood pressure; blurred vision; dizziness. 
- padec krvnega tlaka; motnje vida; omotica.
Fluoroquinolone antibiotics, including Quofenix, may cause levels of glucose in the blood to rise too high or fall too low. 
Fluorokinolonski antibiotiki, vključno z zdravilom Quofenix, lahko povzročijo previsoke ali prenizke ravni glukoze v krvi.
Arthritis reactive 
Reaktivni artritis
This medicine contains 175 mg of sodium (main component of cooking salt) in each vial. 
To zdravilo vsebuje 175 mg natrija (glavne sestavine kuhinjske soli) na vialo.
For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6. 
Za navodila o rekonstituciji in redčenju zdravila pred uporabo glejte poglavje 6.6.
• You have experienced a previous episode of aortic dissection (a tear in the aorta wall). 
• ste ţe kdaj doţiveli epizodo aortne disekcije (raztrganina aortne stene);
Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to delafloxacin in vitro. 
V kliničnih študijah je bila dokazana učinkovitost za naslednje patogene, ki so bili in vitro občutljivi na delafloksacin.
• You have or may have problems with the central nervous system (e.g. severe cerebral arteriosclerosis, epilepsy) or have other risk factors that may put you at more risk of having seizures (fits). 
• imate ali ste imeli teţave z osrednjim ţivčnim sistemom (npr. huda cerebralna arterioskleroza, epilepsija) ali imate druge dejavnike tveganja, zaradi katerih obstaja večja nevarnost napada krčev.
The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation. 
Imetnik dovoljenja za promet z zdravilom mora prvo PSUR za to zdravilo predloţ iti v 6 mesecih po pridobitvi dovoljenja za promet.
• You may have a severe skin reaction such as blistering or lesion. 
• ste kdaj imeli hude koţne reakcije, kot so mehurji ali lezije.
Pharmacokinetic/pharmacodynamic relationship 
Farmakokinetično/farmakodinamična povezava
• Decrease of special blood cells necessary for blood clotting 
• zmanjšano število posebnih krvnih celic, potrebnih za strjevanje krvi
There are no significant circulating metabolites (mean=9.6%) in humans. 
Pri ljudeh ni pomembnih presnovkov v obtoku (povprečna vrednost = 9,6%).
In the two major trials in ABSSSI the types of infections treated were confined to cellulitis/erysipelas, abscesses and wound infections only. 
V dveh večjih preskušanjih z ABSSSI so bile vrste zdravljenih okuţ b, omejene samo na celulitis/šen, abscese in okuţ be ran.
This is equivalent to 8.8% of the recommended maximum daily dietary intake of sodium for an adult. 
To je enako 8,8% priporočenega največjega dnevnega vnosa natrija s hrano za odrasle osebe.
It is available in packs containing 10 vials. 
Na voljo je pakiranje po 10 vial.
If Clostridioides difficile-associated disease is suspected or confirmed treatment with delafloxacin should be discontinued and appropriate supportive measures together with the specific antibacterial treatment of C. difficile should be considered. 
Če obstaja sum na ali potrditev bolezni, povezane s Clostridioides difficile, je treba zdravljenje z delafloksacinom prekiniti in razmisliti o ustreznih podpornih ukrepih, skupaj s specifičnim protibakterijskim zdravljenjem C. difficile.
At the first sign of pain or inflammation of a tendon (for example in your ankle, wrist, elbow, shoulder or knee), stop taking Quofenix, contact your doctor and rest the painful area. 
Ob prvem znaku bolečine ali vnetja tetiv (na primer v gleţ nju, zapestju, komolcu, rami ali kolenu) prenehajte jemati zdravilo Quofenix, posvetujte se z zdravnikom in pustite, da prizadeti ud miruje.
Delafloxacin inhibits bacterial topoisomerase IV and DNA gyrase (topoisomerase II), enzymes required for bacterial DNA replication, transcription, repair, and recombination. 
Delafloksacin zavira bakterijsko topoizomerazo IV in DNA-girazo (topoizomeraza II), encime, potrebne za podvajanje bakterijske DNA, prepisovanje, popravljanje in rekombinacijo.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. 
Pred začetkom jemanja uporabe zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
Other medicines and Quofenix 
Druga zdravila in zdravilo Quofenix
Quofenix must not be used if you are pregnant or breast-feeding. 
Zdravila Quofenix se ne sme uporabljati med nosečnostjo ali dojenjem.
Pharmacokinetic parameters are not altered in obese patients (BMI ≥ 30 kg/m2). 
Pri bolnikih s prekomerno telesno maso se farmakokinetični parametri ne spremenijo (BMI ≥ 30 kg/m
• If you are allergic to any other fluoroquinolone or quinolone antibacterial medicine. 
• Če ste alergični na katero koli drugo fluorokinolonsko ali kinolonsko protibakterijsko zdravilo.
If you feel sudden, severe pain in your abdomen, chest or back, go immediately to an emergency room. 
Če v trebuhu, prsih ali hrbtu začutite nenadno hudo bolečino, takoj obiščite urgentno ambulanto.
The safety and efficacy of the dose recommendation in patients with severe renal impairment has not been clinically evaluated and is based on pharmacokinetic modelling data. 
Varnosti in učinkovitosti priporočenega odmerka pri bolnikih s hudo okvaro ledvic niso klinično ocenili in temelji na podatkih farmakokinetičnega modeliranja.
- Abdominal (belly) pain with possible severe diarrhoea; fever and nausea. 
- abdominalna bolečina (bolečina v trebuhu) z moţ no hudo drisko; vročina in slabost.
Corticosteroids should not be used if signs of tendinopathy occur (see section 4.8). 
Če se pojavijo znaki tendinopatije, se ne sme uporabiti kortikosteroidov (glejte poglavje 4.8).
Prolonged, disabling and potentially irreversible serious side effects 
Dolgotrajni, onesposabljajoči in potencialno ireverzibilni resni neţ eleni učinki
Injection/infusion site reaction 
Reakcije na mestu injiciranja/infundiranja
• Worsening of a wound 
• poslabšanje stanja rane
The safety and efficacy of the dose adjustment guidance in patients with severe renal impairment has not been clinically evaluated and is based on pharmacokinetic modelling data. 
Varnost in učinkovitost prilagajanja odmerka pri bolnikih s hudo okvaro ledvic ni bila klinično ocenjena in temelji na podatkih farmakokinetičnega modeliranja.
Musculoskeletal and connective tissue disorders* 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva*
The following adverse reactions have been identified in four comparative ABSSSI Phase 2 and 3 studies classified by preferred term and System Organ Class, and by frequency. 
Naslednji neţ eleni učinki, ki so bili zaznani v štirih primerjalnih študijah ABSSSI faze 2 in 3, so navedeni po prednostnih izrazih in organskih sistemih in razvrščeni po pogostnosti.
As per fluoroquinolone class patients aged over 60 years are at increased risk for developing severe tendon disorders including tendon rupture (see sections 4.4 and 
Pri zdravilih iz skupine fluorokinolonov za bolnike, starejše od 60 let, obstaja večje tveganje za razvoj hudih teţ av s tetivami, vključno z rupturo tetive (glejte poglavji 4.4 in 5.2).
Based on in vitro data on metabolising enzymes and transporters delafloxacin possesses a low potential to alter the disposition of other medicinal products (see section 5.2). 
Na podlagi in vitro podatkov o presnavljajočih encimih in prenašalcih, ima delafloksacin majhen potencial za spremembo učinka drugih zdravil (glejte poglavje 5.2).
Quofenix is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1). 
Zdravilo Quofenix je indicirano za zdravljenje akutnih bakterijskih okuţ b koţ e in koţ nih struktur (ABSSSI - acute bacterial skin and skin structure infections) pri odraslih, kadar uporaba drugih protibakterijskih zdravil, ki se običajno priporočajo za začetno zdravljenje teh okuţ b, ni primerna (glejte poglavji 4.4 in 5.1).
However, delafloxacin should not be co-administered with any solution containing multivalent cations, e.g. magnesium, through the same intravenous line (see section 4.2 and 
Vendar pa se delafloksacina skozi isto intravensko linijo ne sme dajati skupaj z nobeno raztopino, ki vsebuje večvalentne katione, npr. magnezij (glejte poglavji 4.2 in 6.2).
There are no or limited amount of data from the use of delafloxacin in pregnant women. 
O uporabi delafloksacina pri nosečnicah podatkov ni ali so omejeni.
Quofenix is an antibiotic that contains the active substance delafloxacin. 
Zdravilo Quofenix je antibiotik, ki vsebuje učinkovino delafloksacin.
Therefore, delafloxacin should be used with caution in these patients. 
Zato je pri teh bolnikih delafloksacin treba uporabljati previdno.
Delafloxacin is excreted both unchanged and as glucuronide metabolites in urine. 
Delafloksacin se izloča v nespremenjeni obliki in kot presnovki glukuronida v urinu.
Quofenix must not be co-infused with other medications. 
Zdravila Quofenix ne smete infundirati sočasno z drugimi zdravili.
• Muscle weakness in the extremities 
• mišična šibkost v okončinah
It is available in perforated unit dose blister pack which contains blisters of 10x1 tablets into pack size of 10,20,30,50, 60 or 100 tablets per carton. 
Na voljo so v perforiranih deljivih pretisnih omotih s posameznimi odmerki, ki vsebujejo pretisne omote po 10x1 tableto in so pakirani v škatle z 10, 20, 30, 50, 60 ali 100 tabletami.
The use of delafloxacin should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). 
Izogibati se je potrebno uporabi delafloksacina pri bolnikih, ki so imeli v preteklosti resne neţ elene učinke pri uporabi zdravil, ki vsebujejo kinolon ali fluorokinolon (glejte poglavje 4.8).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve:
• Inflammation of joints, pain in hands or feet, back pain, muscle spasm 
• vnetje sklepov, bolečine v dlaneh in stopalih, bolečina v hrbtu, mišični krči
Medicinal products inhibiting the peristalsis are contraindicated if Clostridioides difficile-associated disease is suspected. 
Zdravila, ki zavirajo peristaltiko, so kontraindicirana, če obstaja sum na bolezen, povezano s Clostridioides difficile.
If women of a sexually mature age are treated, effective contraception must be used during treatment (see section 4.6). 
Če se zdravijo spolno zrele ţ enske, je treba med zdravljenjem uporabiti učinkovito kontracepcijo (glejte poglavje 4.6).
In rats foetal effects occurred at a level of exposure exceeding about 2fold that observed in humans based on the AUC, but in rabbits, a species known to be extremely sensitive to maternal toxicity of antibacterial drugs, the effects on foetuses were recorded at levels of exposure well below that observed in humans. 
Pri podganah so se pojavili učinki na plod pri izpostavljenosti, ki je bila pribliţ no 2krat višja kot pri ljudeh, ob upoštevanju AUC, medtem ko so pri kuncih, za katere je znano, da so zelo občutljivi na toksičnost protibakterijskih zdravil, učinke na plod opazili pri ravneh izpostavljenosti precej pod izpostavljenostjo, ki je primerna za človeka.
These adverse reactions may occur following the first dose. 
Ti neţ eleni učinki se lahko pojavijo po prvem odmerku.
This medicine contains 39 mg of sodium (main component of cooking salt) in each tablet. 
To zdravilo vsebuje 39 mg natrija (glavne sestavine kuhinjske soli) na tableto.
• Streptococcus mitis group (including Streptococcus cristatus, Streptococcus gordonii, 
• Skupina Streptococcus mitis (vključno s Streptococcus cristatus, Streptococcus gordonii,
The most common adverse drug reactions reported in ABSSSI Phase 2 and 3 studies involving 868 patients exposed to delafloxacin, intravenous or oral formulation, were diarrhoea and nausea (6.91% and 7.83%, respectively) which were mild to moderate in intensity. 
Najpogostejši neţ eleni učinki, o katerih so poročali v študijah faze 2 in 3 ABSSSI, ki so vključevale 868 bolnikov, ki so bili izpostavljeni delafloksacinu, bodisi v intravenski ali peroralni obliki, sta bili driska in navzea (6,91 % oziroma 7,83 %), ki sta bili blagi do zmerno intenzivni.
Peak exposure (Cmax) was not statistically significantly different between renal impaired and healthy subjects. 
Najvišja izpostavljenost (Cmax) ni bila statistično pomembno različna za bolnike z ledvično okvaro in za zdrave osebe.
Quofenix is a beige to mottled beige, oblong biconvex tablets, with RX3341 debossed on one side. 
Quofenix tablete so beţ do pikčasto beţ barve, podolgovate bikonveksne tablete z vtisnjeno oznako RX3341 na eni strani.
Quofenix has moderate influence on the ability to drive and use machines. 
Zdravilo Quofenix ima zmeren vpliv na sposobnost voţ nje in upravljanja strojev.
No dose adjustment is necessary in patients with mild to moderate renal impairment (CrCl of ≥30 mL/min). 
Pri bolnikih z blagimi do zmernimi motnjami v delovanju ledvic, prilagoditev odmerka ni potrebna (CrCl ≥ 30 ml/min).
This medicinal product contains sulfobutylbetadex sodium. 
To zdravilo vsebuje natrijev sulfobutilbetaciklodekstrin.
The glucuronidation of delafloxacin is mediated mainly by UGT1A1,UGT1A3 and UGT2B15. 
Glukuronidacijo delafloksacina posredujejo večinoma UGT1A1, UGT1A3 in UGT2B15.
20 ml clear type I glass vials outfitted with 20 mm type I rubber stoppers and 20 mm flip-off caps. 
20-ml prozorne viale iz stekla tipa I so zaprte z gumijastim zamaškom tipa I velikosti 20 mm in 20 mm pokrovčki (flip-off).
Delafloxacin may be administered with or without food as total systemic exposure (AUC∞) is unchanged between fasted and fed (high-fat, high-calorie) conditions. 
Delafloksacin se lahko vzame s hrano ali brez nje, saj ostane skupna sistemska izpostavljenost (AUC∞) nespremenjena ne glede na to ali se ga vzame pred ali po obroku (bogat z maščobami, visoko kalorični).
Hypoglycaemia (see section 4.4) Hyperglycaemia (see section 4.4) Decreased appetite 
Hipoglikemija (glejte poglavje 4.4) Hiperglikemija (glejte poglavje 4.4) Zmanjšan apetit
Glucuronidation of delafloxacin is the primary metabolic pathway with oxidative metabolism representing <1% of an administered dose. 
Glukuronidacija delafloksacina je glavna presnovna pot, oksidativna presnova, ki predstavlja < 1 % apliciranega odmerka.